Update: The Era of Hope website now contains a link to the Era of Hope Conference press briefing. The first principal investigator interviewed in the briefing is Dr. Georgel. You may listen to the briefing and view the accompanying PowerPoint presentation on the Era of Hope Conference multimedia page.
The following story originally ran on EurekAlert!: http://www.eurekalert.org/pub_releases/2011-08/udod-rld080111.php
Era of Hope conference to feature compelling research examining benefits to daughters based on mother’s diet
Dr. Philippe Georgel recently traveled to San Antonio to present his research at the 20th International Analytical Ultracentrifugation Conference.
ORLANDO, Fla. — August 3, 2011 — During pregnancy, women are counseled to refrain from consuming certain types of foods, beverages and medications in order to avoid jeopardizing the health and development of the fetus. In fact, the American Pregnancy Association has a list of a dozen items they recommend expectant mothers omit from their diets. However, there are some additions, such as folic acid, that, when taken before and/or during pregnancy, can actually reduce the risk of birth defects and other disorders.1 Research presented today at the Era of Hope conference, a scientific meeting hosted by the Department of Defense Breast Cancer Research Program (BCRP), reveals findings suggesting that if an expectant mother increases her consumption of foods high in certain fatty acids or nutrients during her pregnancy, she can potentially reduce the risk of breast cancer in her female offspring.
The research delves into breast cancer risk reductions attributed to the fetus when the mother, while pregnant, increases omega 3 fatty acids within her diet or consumes dietary methyl nutrients (methionine, choline, folate and vitamin B12). Some findings hypothesize that these diet augmentations may even prevent breast cancer from ever developing in the offspring.
“This is exciting and intriguing research,” said Captain Melissa Kaime, M.D., Director of the Congressionally Directed Medical Research Programs (CDMRP), under which the BCRP is managed. “To be able to reduce the risk and possibly prevent this devastating disease before birth is an incredible notion; the BCRP is proud to support research with such potential.”
Maternal Consumption of Omega 3 Fatty Acids to Reduce Breast Cancer Risk in Offspring
Principal Investigator: Philippe T. Georgel, PhD, Marshall University
Maternal dietary alterations, including increasing the consumption of omega 3 fatty acids, may reduce the risk of breast cancer to the fetus by causing epigenetic changes in utero and later through nursing. These changes may alter gene expression permanently, a change referred to as imprinting. Researchers at Marshall University conducted a study to investigate whether having a diet rich in omega 3s while pregnant would result in changes to fetal mammary gland gene expression, thereby reducing the chance that female offspring would later develop breast cancer.
In this study, there was a reduced incidence of mammary gland cancer observed for the offspring of mice that, while pregnant and nursing, consumed a diet containing canola oil, rich in omega 3, compared with the offspring of mice that, while pregnant and nursing, consumed a diet containing corn oil rich in omega 6 fatty acids. Reviewing the gene expression profiles of both groups showed that many genes related to cancer development differed between the two groups. Significant differences in the patterns of two important epigenetic markers were also observed.
“Pregnant women should be mindful of what they consume since their diet may incite epigenetic changes that could impact the development of their offspring, not just in utero but also for time to come,” said Dr. Philippe Georgel, Marshall University. “Additional research continues, as we seek to elucidate the effect of diet on breast cancer-specific gene expression.”
About the Era of Hope
The Era of Hope (EOH) conference joins scientists, clinicians and breast cancer advocates committed to advancing research on the prevention, detection, diagnosis and treatment of breast cancer. From August 2-5, 2011 in Orlando, Florida, the EOH will feature prominent scientists and clinicians with presentations of recent remarkable advances in breast cancer research funded by the Department of Defense Breast Cancer Research Program (BCRP). This research challenges paradigms and pushes boundaries to identify innovative, high-impact approaches for future breast cancer research and discoveries.
The EOH conference is recognized as one of the premier breast cancer research conferences, and this year marks the sixth conference of its kind. The EOH will bring together more than 1,600 BCRP awardees, advocates, and invited speakers in an atmosphere of collaborative thinking in the fight against breast cancer. The EOH is a unique opportunity for advocates and expert scientists from different fields and research areas to discuss unanswered questions, share ideas, identify promising directions in breast cancer research, and develop collaborative partnerships. The conference will unveil innovative research and discoveries that are essential to ultimately eradicating the disease.
About the Congressionally Directed Medical Research Programs
In the early 1990s, the breast cancer advocacy community launched a grassroots effort to raise public awareness for the crucial need of increased funding in breast cancer research. Beginning in fiscal year 1992 (FY92), Congress appropriated $25 million for breast cancer research to be managed by the Department of Defense. The following year, Congress continued to respond to the advocacy movement and appropriated $210 million for breast cancer research, marking the beginning of the Congressionally Directed Medical Research Programs (CDMRP). The CDMRP represents a unique partnership among the public, Congress and the military. Because of continued and expanded advocacy efforts, the CDMRP has grown to encompass multiple targeted programs spanning cancer research, military medical research, and other disease, injury or condition specific research. The CDMRP has received $6.525 billion in appropriations from its inception through FY11 and more than 10,000 awards have been made across 25 different programs through FY10. For more information about the CDMRP, please visit http://www.cdmrp.army.mil